Catalog No.
DHC82802
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Extrinsic pathway inhibitor, Lipoprotein-associated coagulation inhibitor, TFPI, EPI, LACI, TFPI1, Tissue factor pathway inhibitor
Concentration
0.73 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P10646
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Anti-TFPI, NN7415, mab2021, CAS: 1312299-39-0
Clone ID
Concizumab
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results, PMID: 31444162
Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab, PMID: 29845491
Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: Results from a rabbit haemophilia bleeding model, PMID: 31609513
Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits, PMID: 30614620
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data, PMID: 30408848
A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A, PMID: 30137664
Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay, PMID: 28594458
A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies, PMID: 31394258
The availability of new drugs for hemophilia treatment, PMID: 32515633
Concizumab: a novel anti-TFPI therapeutic for hemophilia, PMID: 33570646
Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine, PMID: 31676141
Non-factor replacement therapy for haemophilia: a current update, PMID: 29517971
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial, PMID: 25641556
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration, PMID: 24568891
Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses, PMID: 33819375
Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab, PMID: 29931593
Investigational drugs to treat hemophilia, PMID: 32008381
Hemophilia in a Changing Treatment Landscape, PMID: 31030810
Balancing act, PMID: 25597120
Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor, PMID: 24393663
Prophylactic treatment in hemophilic patients with inhibitors, PMID: 31517711
Advances in the Treatment of Hemophilia: Implications for Laboratory Testing, PMID: 30282700
Current and emerging biologics for the treatment of hemophilia, PMID: 31039049
New therapies using nonfactor products for patients with hemophilia and inhibitors, PMID: 30559263
TFPI blockade: removing coagulation's brakes, PMID: 31778542
Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors, PMID: 26637698
Emerging drugs for the treatment of hemophilia A and B, PMID: 27547884
Hemostatic properties of a TFPI antibody, PMID: 22405586
Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era, PMID: 32955428
Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status, PMID: 30146094
Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors, PMID: 30093246
Alternative therapies for the management of inhibitors, PMID: 27405674
The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody, PMID: 29765291
Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management, PMID: 34026796
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys, PMID: 33810898
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel, PMID: 33843253
Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses, PMID: 31249918
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model, PMID: 22563084
For research use only. Not for human or drug use.
